Tarceva Cancer Drug

In this decade, oncology has been one of the segments of growth among the largest pharmaceutical markets with a focus on targeted agents (medication developed to preferentially target the signaling pathways that are deregulated in tumors). Most innovations in oncology over the past 10 years has been driven by scientific advances, including genomics, transcriptomics and proteomics.

In the present context, the players in oncology future success will be those who can anticipate the evolution of the protocol and the design of clinical trials the most relevant. In recent years, biotechnology companies have fueled innovation in oncology, more than ever. In partnership with biotech companies is a key component (but expensive) source of innovation for many pharmaceutical companies to about 75% of Phase II, III and pre-registration innovative medicines are derived from biotechnology.

At $ 47.7bn, cancer is one of the largest, fastest growing markets in the pharmaceutical industry. However, the price risk is the concern of key investments in oncology. The main concern, however, is not a price erosion driven by competitive forces, but price cuts imposed by payers, regardless of whether such price reductions by unilateral payers have never occurred in one major developed markets and would probably jeopardize the premise on which all of the biopharmaceutical industry has been built.

The main features of this report

• The epidemiological analysis of prevalence and prediction of indications of major cancers in the period 2008-14, including lung, breast, colorectal, ovarian cancer markets.
• The forecast and analysis of key products in the cancer market over the period 2008-14 divided on the main points and types of treatments.
• Overview of key events in the global market for cancer that have influenced patterns of processing and sales potential through the guidance of major cancers.
• Strategic Analysis and the growth of large pharmaceutical companies based on sales point class of drugs, the products currently on the market and R & D portfolio of products.

Scope of this report

• Develop an overview of patient potential with a cover of the report segment information on cancer, the seven largest geographic markets and 10 largest pharmaceutical companies in the segment of cancer today
• Quickly understand how recent events affect the performance of key products and how their marketers are faced with changes in the cancer market competition
• Earn up to date competitive intelligence on the indications of cancer and understand the major issues affecting key pharmaceutical / biotech players
• Understand the indications have the greatest potential for growth franchise, and how pharmaceutical companies attempt to exploit these opportunities

Market issues

• FDA approves Cervarix cervical cancer

In October 2009, FDA approved GSK's Cervarix for the prevention of precancerous lesions caused by human papillomavirus (HPV) types 16 and 18 among women aged 10-25 years. Cervarix inclusion in the vaccination program for children is an important step towards obtaining a refund. Cervarix, is expected to launch by the end of 2009, faces direct competition from Merck's Gardasil and will help reduce the incidence of cancer of the cervix uteri in the future.

• Merck's Gardasil adds indication of U.S. genital warts in boys and men

On October 16, 2009, the Gardasil label in the United States has been expanded to include its use in men and boys aged 9 to 26 years. The results showed a pivotal efficacy of 90.4%, while preventing external genital lesions HPV types 6/11/16/18. In addition, Merck also p.